Harvard Bioscience (HBIO) Cash & Equivalents (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Cash & Equivalents data on file, last reported at $7.1 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $7.1 million, up 27.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.1 million (up 27.98% YoY), and the FY2025 annual result was $8.6 million, up 109.69% from the prior year.
• Cash & Equivalents eased to $7.1 million in Q1 2026 per HBIO's latest filing, from $8.6 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $8.6 million in Q4 2025 and troughed at $3.8 million in Q1 2023.
• A 5-year average of $5.3 million and a median of $4.6 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents plunged 42.36% in 2022, then jumped 109.69% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $4.5 million in 2022, then retreated by 4.99% to $4.3 million in 2023, then declined by 4.09% to $4.1 million in 2024, then jumped by 109.69% to $8.6 million in 2025, then dropped by 17.6% to $7.1 million in 2026.
• Business Quant data shows HBIO's Cash & Equivalents at $7.1 million in Q1 2026, $8.6 million in Q4 2025, and $6.8 million in Q3 2025.